Grant: Catalyst Grant: NWHRI: Innovation Fund - Biomedical Discovery Grants
McGill University
$117,400.00
Targeting inhibin B action to regulate follicle-stimulating hormone production and female fertility
EF 2023-24
Résumé
Infertile couples often seek assisted reproductive technologies to become pregnant and have children. Frequently, women are treated with follicle-stimulating hormone (FSH) to promote the growth of the ovarian follicles from which eggs can be retrieved for in vitro fertilization (IVF). FSH must be given daily for as many as two weeks, which is both invasive and expensive. Our laboratory is trying to develop new approaches to circumvent daily injections. FSH is a hormone made naturally in the pituitary gland, which sits at the base of the brain. Normally, there is a transient elevation of FSH during the menstrual cycle, which stimulates the growth of the follicle that will ovulate (release the egg) that month. Increasing the amount of FSH and/or the time (duration) during which it is elevated can lead to multiple follicles that are capable of ovulating in a given cycle. In response to FSH, ovarian follicles grow and make hormones that feedback to the brain and pituitary gland. One of these hormones, inhibin B, acts directly on pituitary cells to suppress FSH production and secretion. We recently discovered a new receptor for inhibin B. If a hormone is thought of as a key, then the receptor is the lock into which the key uniquely fits to have its effects. We hypothesize that this receptor provides the basis for the development of two new drugs that can increase FSH levels by blocking or impairing inhibin B action. One drug will bind to the inhibin B receptor blocking inhibin B binding. The second will bind and sequester inhibin B in the blood, decreasing its actions in the pituitary gland. In both cases, a single injection should increase FSH levels, leading to the stimulation of several ovarian follicles from which eggs can be ovulated and fertilized. The goal of the present project is to develop the drugs and begin testing their activities in cells and animal models.
Programme
Catalyst Grant: NWHRI: Innovation Fund - Biomedical Discovery Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486701
Name
Bernard Daniel J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
NWHRI: Innovation Fund - Biomedical Discovery Grants
Projecttitle
Targeting inhibin B action to regulate follicle-stimulating hormone production and female fertility
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$117,400
Cihrequipment2
$0
Programname2
Catalyst Grant: NWHRI: Innovation Fund - Biomedical Discovery Grants
Keyworddelim
Antagonist; Antibody; Cell Culture; Fertility; Fsh; Inhibin; Ligand Trap; Mouse; Pituitary; Reproduction
Abstract
Infertile couples often seek assisted reproductive technologies to become pregnant and have children. Frequently, women are treated with follicle-stimulating hormone (FSH) to promote the growth of the ovarian follicles from which eggs can be retrieved for in vitro fertilization (IVF). FSH must be given daily for as many as two weeks, which is both invasive and expensive. Our laboratory is trying to develop new approaches to circumvent daily injections. FSH is a hormone made naturally in the pituitary gland, which sits at the base of the brain. Normally, there is a transient elevation of FSH during the menstrual cycle, which stimulates the growth of the follicle that will ovulate (release the egg) that month. Increasing the amount of FSH and/or the time (duration) during which it is elevated can lead to multiple follicles that are capable of ovulating in a given cycle. In response to FSH, ovarian follicles grow and make hormones that feedback to the brain and pituitary gland. One of these hormones, inhibin B, acts directly on pituitary cells to suppress FSH production and secretion. We recently discovered a new receptor for inhibin B. If a hormone is thought of as a key, then the receptor is the lock into which the key uniquely fits to have its effects. We hypothesize that this receptor provides the basis for the development of two new drugs that can increase FSH levels by blocking or impairing inhibin B action. One drug will bind to the inhibin B receptor blocking inhibin B binding. The second will bind and sequester inhibin B in the blood, decreasing its actions in the pituitary gland. In both cases, a single injection should increase FSH levels, leading to the stimulation of several ovarian follicles from which eggs can be ovulated and fertilized. The goal of the present project is to develop the drugs and begin testing their activities in cells and animal models.
Competitiondate
202307
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bernard, Daniel J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $117,400~ $0~